![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page1208.jpg)
Eligible patients:
CD20-postiive FL, WM, MZL,
SLL, MCL (elderly)
No previous treatment
Stage III or IV
R
A
N
D
O
M
I
s
E
Bendamustine-Rituximab (BR)
Bendamustine 90 mg/m
2
days 1-2
Rituximab 375 mg/m
2
day 1
CHOP-Rituximab (R-CHOP)
Cyclophosphamide 750 mg/m
2
day 1
Doxorubicin 50 mg/m
2
day 1
Vincristine 1.4 mg/m
2
day 1
Prednisone 100 mg/days days 1-5
Rituximab 375 mg/m
2
day 1
Primary objective
To prove the
non-inferiority of BR vs. R-CHOP
defined as a decrease of < 10% in progression-
free survival (PFS) after 3 years
Secondary objectives
Time to next treatment (TTNT), event-free survival (EFS), overall survival (OS)
Acute and late toxicities, infectious complications
Stem cell mobilization capacity in younger patients
(n = 549)
BR vs. R-CHOP as First Line Treatment in Patients with Indolent and
Mantle Cell Lymphomas (MCL): Updated Results from the StiL
NHL1 Study